Breathe Well Live Well
Lung Disease News |
Teva's DuoResp Spiromax For Asthma, COPD Wins Medical Design Award
Lung Disease News We are incredibly proud to be leading the way in providing people with asthma and COPD with inhalers that recognize and support their needs and long term health, and are delighted with this prestigious acknowledgment for DuoResp Spiromax,” noted Rob … |
View full post on asthma – Google News
Condition: Patient Satisfaction
Intervention: Drug: Budesonide, Formoterol Fumarate Dihydrate
Sponsor: Teva Pharma GmbH
Active, not recruiting – verified March 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Teva's DuoResp Spiromax receives EC marketing authorization for treatment of …
News-Medical.net Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the European Commission has granted marketing authorization for DuoResp Spiromax® for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) … Teva Gets Approval To Market DuoResp Spiromax In Europe |
View full post on asthma – Google News
|
Teva's DuoResp Spiromax gets positive CHMP opinion to treat asthma and COPD
Pharmaceutical Business Review DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid for the treatment of underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting … Teva's Symbicort generic backed for EU approval 10 new medicines recommended for approval in Europe |
View full post on asthma – Google News
|
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …
RTT News DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 … EU Agency backs respiratory drugs for approval EMA Backs Generic Versions of AstraZeneca's Symbicort |
View full post on asthma – Google News
|
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …
NASDAQ DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 … UPDATE 1-EU Agency backs respiratory drugs for approval EMA Backs Generic Versions of AstraZeneca's Symbicort |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX; Drug: SYMBICORT TURBOHALER budesonide and formoterol fumarate
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified February 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Albuterol Spiromax; Drug: ProAir HFA; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting – verified July 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting – verified May 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days